We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
-14.07%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$55.8M
AUM Growth
-$10.5M
(-16%)
Cap. Flow
-$1.3M
Cap. Flow
% of AUM
-2.34%
Top 10 Holdings %
Top 10 Hldgs %
93.44%
Holding
16
New
1
Increased
4
Reduced
7
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zymeworks
ZYME
|
+$1.15M |
| 2 |
Precision BioSciences
DTIL
|
+$966K |
| 3 |
Arvinas
ARVN
|
+$501K |
| 4 |
Protagonist Therapeutics
PTGX
|
+$214K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$4.46M |
| 2 |
Arrowhead Research
ARWR
|
+$2.86M |
| 3 |
SLN
Silence Therapeutics
SLN
|
+$2.53M |
| 4 |
Kymera Therapeutics
KYMR
|
+$1.64M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$592K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Amgen
AMGN
$222B
| $18.7M | 33.51% |
60,000
+35,000
| +140% | +$10.3M |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $7.43M | 13.32% |
83,926
-45,674
| -35% | -$4.46M |
|
|
3
Arrowhead Research
ARWR
$12.4B
| $7.01M | 12.57% |
550,130
-157,459
| -22% | -$2.86M |
|
|
4
Protagonist Therapeutics
PTGX
$9.44B
| $3.95M | 7.08% |
81,692
+5,100
| +7% | +$214K |
|
|
5
Kymera Therapeutics
KYMR
$8.94B
| $3.79M | 6.8% |
138,521
-45,000
| -25% | -$1.64M |
|
|
6
Precision BioSciences
DTIL
$207M
| $3.46M | 6.21% |
726,149
+189,773
| +35% | +$966K |
|
|
7
Arvinas
ARVN
$572M
| $2.53M | 4.54% |
360,766
+32,000
| +10% | +$501K |
|
8
Regenxbio
RGNX
$708M
| $1.94M | 3.48% |
271,302
-75,000
| -22% | -$558K |
|
9
Adicet Bio
ACET
$74.7M
| $1.85M | 3.32% |
153,512
-4,688
| -3% | -$67K |
|
|
BCYC
10
Bicycle Therapeutics
BCYC
$292M
| $1.46M | 2.61% |
171,695
-50,216
| -23% | -$592K |
|
11
Immatics
IMTX
$1.32B
| $1.38M | 2.47% |
304,902
-69,000
| -18% | -$360K |
|
|
RPTX
12
DELISTED
Repare Therapeutics
RPTX
| $1.28M | 2.29% |
1,293,715
| – | – |
|
|
13
Zymeworks
ZYME
$1.67B
| $1.01M | 1.8% |
+84,482
| New | +$1.15M |
|
|
14
CALL
Arrowhead Research
ARWR
$12.4B
| – | – |
-75,000
| Closed | -$1.41M |
|
|
SLN
15
Silence Therapeutics
SLN
$564M
| – | – |
-367,214
| Closed | -$2.53M |
|
16
Sutro Biopharma
STRO
$421M
| – | – |
-50
| Closed | -$916 |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Aquilo Capital Management held 16 positions worth $55.8M, down 16% from $66.3M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Aquilo Capital Management's Q1 2025 filing shows 1 new, 4 increased, 7 reduced and 3 closed positions. Its largest new stake was Zymeworks: 84,482 shares worth $1.01M. The largest sale was Blueprint Medicines, an estimated $4.46M.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 88% a quarter earlier.
- Aquilo Capital Management's largest Q1 2025 buy was Zymeworks: 84,482 shares worth $1.01M.
- Aquilo Capital Management added most to Precision BioSciences in Q1 2025, an estimated $966K increase.
- Aquilo Capital Management's biggest Q1 2025 reduction was Blueprint Medicines, cutting an estimated $4.46M.
- Aquilo Capital Management fully exited Silence Therapeutics in Q1 2025, selling an estimated $2.53M.
- Aquilo Capital Management's ten largest holdings make up 93% of its $55.8M portfolio in Q1 2025.
- Aquilo Capital Management opened 1 new position and closed 3 in Q1 2025.
- Aquilo Capital Management's portfolio value fell 16% quarter-over-quarter to $55.8M.
Based on Aquilo Capital Management's 13F filing for Q1 2025, filed 15 May 2025.